Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	The Hydration Pharmaceuticals Company Limited
ACN	620 385 677

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Joseph Constable
Date of last notice	11 April 2025

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct / Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Joseph Constable     Dr Ida Constable*  *Joseph Constable has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.	
Date of change	1. 4 June 2025 2. 4 June 2025	
No. of securities held prior to change		
Joseph Constable	91,080 fully paid ordinary shares	
Dr Ida Constable*	32,500,000 fully paid ordinary shares	
Donus Australia Foundation Limited*	27,500,000 fully paid ordinary shares	
*Joseph Constable has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.		
Class	Fully Paid Ordinary Shares	
Number acquired	<ol> <li>1. 142,857 fully paid ordinary shares</li> <li>2. 752,531 fully paid ordinary shares</li> </ol>	

<sup>+</sup> See chapter 19 for defined terms.

Number disposed	Nil	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$0.007 per fully paid ordinary share	
No. of securities held after change		
Joseph Constable	233,937 fully paid ordinary shares	
Dr Ida Constable*	33,252,531 fully paid ordinary shares	
Donus Australia Foundation Limited*	27,500,000 fully paid ordinary shares	
*Joseph Constable has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.		
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase	

### Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

### Appendix 3Y Change of Director's Interest Notice

Interest after change	N/A

### Part 3 – \*Closed period

Were the interests in the securities or contracts	No
detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

<sup>+</sup> See chapter 19 for defined terms.